Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncotelic TherapeuticsOTLC -6.01% EV-to-OCF is -18.09 as of Aug. 08, 2026. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Oncotelic Therapeutics ranks better than 80.2% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Oncotelic Therapeutics's Enterprise Value is $28.18 Mil.
Oncotelic Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.56 Mil. Therefore, Oncotelic Therapeutics's EV-to-OCF for today is -18.09.
The historical rank and industry rank for Oncotelic Therapeutics's EV-to-OCF or its related term are showing as below:
OTLC'
s EV-to-OCF Range Over the Past 10 Years
Min: -23.8 Med: -2.69 Max: -1.73
Current: -18.09
During the past 13 years, the highest EV-to-OCF of Oncotelic Therapeutics was -1.73. The lowest was -23.80. And the median was -2.69.
OTLC's EV-to-OCF is ranked better than 80.2% of 1409
companies
in the Biotechnology industry
Industry Median: -3.48
vs OTLC: -18.09
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncotelic Therapeutics's PE Ratio (TTM) for today is calculated as:
Oncotelic Therapeutics's share price for today is $0.03384.
Oncotelic Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.566.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncotelic Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's EV-to-OCF falls into.
Oncotelic Therapeutics's current Enterprise Value is $28.18 Mil.
Oncotelic Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncotelic Therapeutics (OTLC) has a EV-to-OCF of -18.09 as of Aug. 08, 2026. According to the industry distribution chart, Oncotelic Therapeutics ranks #279 out of 1409 companies in the Biotechnology industry, placing it in the top 19.8%.
Is Oncotelic Therapeutics' EV-to-OCF too high?
Oncotelic Therapeutics' current EV-to-OCF is -18.09. Based on the distribution chart, Oncotelic Therapeutics ranks #279 out of 1409 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Oncotelic Therapeutics' EV-to-OCF compare to KTTA and LSTA?
According to the Biotechnology industry distribution chart, Oncotelic Therapeutics ranks #279 out of 1409 companies for EV-to-OCF. This places Oncotelic Therapeutics in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Oncotelic Therapeutics's current EV-to-OCF is -18.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncotelic Therapeutics stock overvalued right now?
Oncotelic Therapeutics (OTLC) has a current EV-to-OCF of -18.09. The current EV-to-OCF is -18.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Oncotelic Therapeutics (OTLC), the current EV-to-OCF is -18.09 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. OT-101 is its flagship immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, AL-101, and Oxi4503.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTLC has been successfully added to your 
